Canada Global (Web News) Cervical cancer patients who take early drugs before standard treatment have a third less chance of dying from this disease, this has been revealed in a study.
Also read this
New paper test developed for early stage cancer diagnosis
Chemoradiation (giving chemotherapy at the same time as radiotherapy) has been standard treatment since 1999, but despite improved techniques, the cancer has a 30 percent chance of recurrence. A team of researchers from University College London followed a 10-year trial of 500 patients. Recruited for All these people were suffering from cervical cancer. Among them, the cancer was so severe that it could be seen without a microscope, but it had not spread. Every patient in the study received standard chemotherapy, but some also received induction chemotherapy beforehand.
read more
New paper test developed for early stage cancer diagnosis
This aggressive treatment (in which drugs try to kill as many cancer cells as possible), which adds to the benefits of chemotherapy, is associated with some risks that are not suitable for everyone. But an early analysis of the study (after five years) found that 80 percent of patients who received both treatments were alive, and 73 percent did not see the cancer return or spread. 100% survived, while 65% did not see the cancer return or spread.
